Gaithersburg, Md – Oct 9 2024
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW), a technology-enabled drug development company utilizing AI and machine learning to drive pharmaceutical advancements, today announced the publication of new research in Cell Reports supporting the potential of its investigational drug candidate, BF-114 (SPTBN1 siRNA), in treating liver diseases linked to obesity, including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), and hepatocellular carcinoma (HCC).
Strengthening the Scientific Foundation for BF-114
The study, led by Dr. Lopa Mishra, a globally recognized expert in liver disease, demonstrates that β2-spectrin, a protein encoded by the SPTBN1 gene, plays a critical role in disease progression. The research provides strong mechanistic evidence that targeting β2-spectrin with BF-114 can mitigate liver disease progression by reducing liver damage and improving metabolic function.
“These findings reinforce the therapeutic potential of BF-114 and its role in transforming liver disease treatment,” said Vin Singh, CEO of BullFrog AI. “Dr. Mishra’s research provides compelling evidence that could redefine treatment options for patients suffering from obesity-driven liver diseases.”
AI-Powered Insights to Accelerate Development
BullFrog AI will leverage its proprietary bfLEAP™ AI platform to analyze single-cell data from animal models and human patients. The insights gained will refine mechanistic understanding and optimize BF-114’s development, potentially expanding its therapeutic applications beyond liver disease.
Dr. Lopa Mishra Joins BullFrog AI’s Scientific Advisory Board
In addition to leading this pivotal study, Dr. Mishra has joined BullFrog AI’s Scientific Advisory Board. With over 100 peer-reviewed publications and an H-Index of 66, Dr. Mishra brings extensive expertise in liver disease research and drug development.
“I am excited to collaborate with BullFrog AI to further explore BF-114’s therapeutic potential,” said Dr. Mishra. “This AI-driven approach to drug discovery holds immense promise for addressing critical unmet needs in liver disease and obesity treatment.”
About BullFrog AI
BullFrog AI is at the forefront of AI-driven drug development, integrating advanced machine learning to enhance the success of pharmaceuticals and biologics. Through strategic collaborations with research institutions, including George Washington University, the company is pioneering new approaches to tackling complex diseases. BullFrog AI’s proprietary bfLEAP™ platform is being utilized to advance BF-114 for the treatment of obesity-related liver diseases.
By
